BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38517412)

  • 1. Extreme Case of Surgical Port Metastasis in Ovarian Cancer.
    Kostrzanowski M; Ziółkowski G; Dąbrowski F
    Oncology (Williston Park); 2024 Mar; 38(3):110-114. PubMed ID: 38517412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
    Rosendahl M; Høgdall CK; Mosgaard BJ
    Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
    Kuhn W; Rutke S; Späthe K; Schmalfeldt B; Florack G; von Hundelshausen B; Pachyn D; Ulm K; Graeff H
    Cancer; 2001 Nov; 92(10):2585-91. PubMed ID: 11745193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Peregrin I; Mendizabal E; Ortiz-Quintana L
    Int J Gynecol Cancer; 2015 Jan; 25(1):49-54. PubMed ID: 25405578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis.
    Xiao Y; Xie S; Zhang N; Wang J; Lv C; Guo J; Yang Q
    Gynecol Obstet Invest; 2018; 83(3):209-219. PubMed ID: 29402804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
    Chekerov R; Braicu I; Castillo-Tong DC; Richter R; Cadron I; Mahner S; Woelber L; Marth C; Van Gorp T; Speiser P; Zeillinger R; Vergote I; Sehouli J
    Int J Gynecol Cancer; 2013 Feb; 23(2):268-75. PubMed ID: 23358178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery.
    Sørensen SM; Schnack TH; Høgdall C
    Acta Obstet Gynecol Scand; 2019 Jan; 98(1):34-43. PubMed ID: 30168853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of pelvic and aortic lymphadenectomy at second look surgery in apparent early stage ovarian cancer after inadequate surgical staging followed by adjuvant chemotherapy.
    Signorelli M; Fruscio R; Ceppi L; Dell'anna T; Vitobello D; Chiappa V; Siesto G; Milani R; Landoni F; Mangioni C
    Gynecol Oncol; 2014 Feb; 132(2):312-5. PubMed ID: 24423881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
    Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
    Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laparoscopic management of advanced epithelial ovarian cancer after neoadjuvant chemotherapy: a phase II prospective multicenter non-randomized trial (the CILOVE study).
    Pomel C; Akladios C; Lambaudie E; Rouzier R; Ferron G; Lecuru F; Classe JM; Fourchotte V; Paillocher N; Wattiez A; Montoriol PF; Thivat E; Beguinot M; Canis M
    Int J Gynecol Cancer; 2021 Dec; 31(12):1572-1578. PubMed ID: 34670829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system.
    Nguyen HN; Averette HE; Hoskins W; Sevin BU; Penalver M; Steren A
    Cancer; 1993 Nov; 72(10):3007-11. PubMed ID: 8221569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pure Immature Teratoma of the Ovary in Adults: Thirty-Year Experience of a Single Tertiary Care Center.
    Alwazzan AB; Popowich S; Dean E; Robinson C; Lotocki R; Altman AD
    Int J Gynecol Cancer; 2015 Nov; 25(9):1616-22. PubMed ID: 26332392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer.
    Ayhan A; Celik H; Taskiran C; Bozdag G; Aksu T
    Eur J Gynaecol Oncol; 2003; 24(3-4):223-32. PubMed ID: 12807228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymph node-positive stage IIIC ovarian cancer: a separate entity?
    Berek JS
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S18-20. PubMed ID: 19955908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancer.
    Angeles MA; Spagnolo E; Cabarrou B; Pérez-Benavente A; Gil Moreno A; Guyon F; Rychlik A; Migliorelli F; Bataillon G; Navarro AS; Betrian S; Ferron G; Hernández A; Martinez A
    Int J Gynecol Cancer; 2023 Jan; 33(1):50-56. PubMed ID: 36446410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study for investigating the relationship between old and new staging systems with prognosis in ovarian cancer using gynecologic cancer registry of Japan Society of Obstetrics and Gynecology (JSOG): disparity between serous carcinoma and clear cell carcinoma.
    Yamagami W; Nagase S; Takahashi F; Ino K; Hachisuga T; Mikami M; Enomoto T; Katabuchi H; Aoki D
    J Gynecol Oncol; 2020 Jul; 31(4):e45. PubMed ID: 32026659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: can the risk be reduced?
    van Dam PA; DeCloedt J; Tjalma WA; Buytaert P; Becquart D; Vergote IB
    Am J Obstet Gynecol; 1999 Sep; 181(3):536-41. PubMed ID: 10486460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.